{
    "clinical_study": {
        "@rank": "53830", 
        "arm_group": [
            {
                "arm_group_label": "Semaglutide", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate the effect of\n      semaglutide on hypoglycaemic counter-regulation compared to placebo in subjects with type 2\n      diabetes."
        }, 
        "brief_title": "A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects diagnosed with type 2 diabetes and on stable treatment for a period of 90\n             days prior to screening with metformin as monotherapy. Stable is defined as unchanged\n             dose\n\n          -  Male or female, age between18-64 years (both inclusive) at the time of signing\n             informed consent\n\n          -  Body Mass Index (BMI) between 20.0-35.0 kg/m^2 (both inclusive)\n\n          -  HbA1c (glycosylated haemoglobin) between 6.5-10.0% (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Treatment with any glucose lowering agent(s) other than metformin in a period of 90\n             days before screening. An exception is short-term treatment (less than or equal to 7\n             days in total) with insulin in connection with intercurrent illness\n\n          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the\n             last 12 months) or hypoglycaemic unawareness as judged by the investigator or\n             hospitalisation for diabetic ketoacidosis during the previous 6 months\n\n          -  Blood or plasma donation within the past month or more than 500 mL within the last 3\n             months prior to first semaglutide dosing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147431", 
            "org_study_id": "NN9535-3684", 
            "secondary_id": [
                "2013-002751-15", 
                "U1111-1144-7019"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Semaglutide", 
                "description": "2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.\nEach treatment period will be followed by a hypoglycaemic clamp", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.\nEach treatment period will be followed by a hypoglycaemic clamp.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hypoglycemic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8036"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in mean glucagon concentration during hypoglycaemia (change from target level 5.5 mmol/L to nadir (target 2.5 mmol/L))", 
            "safety_issue": "No", 
            "time_frame": "After 12 weeks 2 days of treatment in each treatment period (Day 87 and Day 213)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147431"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in mean glucagon concentration from target level 5.5 mmol/L to 3.5 mmoL/L and from ambient plasma glucose to target levels 5.5 mmol/L, 3.5 mmol/L and nadir", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks 2 days of treatment in each treatment period (Day 87 and Day 213)"
            }, 
            {
                "measure": "Change in mean concentrations of adrenaline, noradrenaline, cortisol and growth hormone from target level 5.5 mmol/L to 3.5 mmol/L and to nadir", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks 2 days of treatment in each treatment period (Day 87 and Day 213)"
            }, 
            {
                "measure": "Hypoglycaemic symptoms score", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks 2 days of treatment in each treatment period (Day 87 and Day 213)"
            }, 
            {
                "measure": "Time from termination of insulin infusion at nadir to reach plasma glucose level 4.0 mmol/L", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks 2 days of treatment in each treatment period (Day 87 and Day 213)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}